ADXS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ADXS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Ayala Pharmaceuticals's ROE % for the quarter that ended in Dec. 2023 was 0.00%. Ayala Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2023 was N/A. Ayala Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was N/A.
The historical data trend for Ayala Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ayala Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
ROE % Adjusted to Book Value | Get a 7-Day Free Trial | - | - | -31.89 | - | - |
Ayala Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Jun23 | Sep23 | Dec23 | |
ROE % Adjusted to Book Value | Get a 7-Day Free Trial | -182.43 | - | - | - | - |
For the Biotechnology subindustry, Ayala Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ayala Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Ayala Pharmaceuticals's ROE % Adjusted to Book Value falls into.
Ayala Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as
Ayala Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Ayala Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Yair Chaim Schindel | other: shareholder of 10% holder | YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110 |
Roni Mamluk | director, officer: CEO | CHIASMA, INC., 60WELLS AVENUE, NEWTON MA 02459 |
Gary B. Gordon | officer: Chief Medical Officer | C/O AYALA PHARMACEUTICALS, INC., OPPENHEIMER 4, REHOVOT L3 7670104 |
David Sidransky | director | JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205 |
Vered Bisker-leib | director | C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142 |
Israel Biotech Fund I, L.p. | 10 percent owner | 4 OPPENHEIMER ST., REHOVOT L3 7670104 |
Harel Insurance Co Ltd | 10 percent owner | ABBA HILLEL 3, RAMAT GAN L3 5211802 |
Amoon Growth Fund Limited Partnership | 10 percent owner | 34 YERUSHALAYIM RD., RAANANA L3 4350110 |
Murray A Goldberg | director | 2030 MAIN STREET, SUITE 1500, IRVINE CA 92614 |
Maimon Yossi | officer: CFO | C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100 |
Robert J. Spiegel | director | C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Harel Insurance Investments & Financial Services Ltd. | 10 percent owner | HAREL HOUSE, 3 ABBA HILLEL ST., RAMAT GAN L3 52118 |
Todd Sone | director | C/O AYALA PHARMACEUTICALS, INC., OPPENHEIMER 4, REHOVOT L3 7670104 |
From GuruFocus
By PurpleRose PurpleRose • 07-12-2022
By GuruFocus News • 10-09-2024
By GuruFocus Research • 03-04-2024
By Business Wire Business Wire • 10-19-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
By GuruFocus Research • 03-04-2024
By PurpleRose PurpleRose • 08-24-2022
By GuruFocus Research • 03-04-2024
By GuruFocus Research • 03-04-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.